Abstracts tagged "psoriatic arthritis and remission"

Abstract Number: 303 • 2019 ACR/ARP Annual Meeting
Utility of Power Doppler Ultrasound–Detected Synovitis for the Prediction of Flare in Psoriatic Arthritis Patients in Clinical Remission
Johana Zacariaz Hereter¹, Josefina Marin ², Maria Laura Acosta Felquer ², Martin Brom ³, Javier Rosa ⁴, Ricardo Garcia Monaco ¹ and Enrique Soriano ⁵, ¹Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Hospital Italiano de Buenos Aires, buenos aires, Ciudad Autonoma de Buenos Aires, Argentina, ³Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁴Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, ⁵Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Power Doppler ultrasound (PDUS) has been shown to detect subclinical synovitis in psoriatic arthritis (PsA). The aim of this study was to evaluate PDUS…
Abstract Number: 1535 • 2019 ACR/ARP Annual Meeting
Achievement of Very Low Disease Activity and Remission Treatment Targets Is Associated with Reduced Radiographic Progression in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol
Laura Coates¹, Joseph Merola ², Arthur Kavanaugh ³, Philip Mease ⁴, Owen Davies ⁵, Oscar Irvin-Sellers ⁶, Tommi Nurminen ⁷ and Désirée van der Heijde ⁸, ¹University of Oxford, Oxford, United Kingdom, ²Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ³University of California, San Diego School of Medicine, La Jolla, CA, ⁴Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ⁵UCB Pharma, Slough, England, United Kingdom, ⁶UCB Pharma, Slough, UK, Slough, United Kingdom, ⁷UCB Pharma, Monheim, Germany, ⁸Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Several disease activity measures and thresholds have been recommended as psoriatic arthritis (PsA) treatment targets, although consensus on the most appropriate assessment tool is…
Abstract Number: 636 • 2018 ACR/ARHP Annual Meeting
Remission/Low Disease Activity Is a Reasonable Treatment Target in Psa: Results from a Routine Care European Cohort of Psa Patients Treated with Ustekinumab or TNF Inhibitors
Laure Gossec^1,2, Paul Bergmans³, Kurt de Vlam⁴, Elisa Gremese⁵, Beatriz E. Joven⁶, Tatiana Korotaeva⁷, Michael Nurmohamed^8,9, Petros Sfikakis¹⁰, Stefan Siebert¹¹, Pavel Smirnov¹², Elke Theander¹³ and Josef S. Smolen¹⁴, ¹Rheumatology, Pitié Salpêtrière Hospital, Paris, France, ²Rheumatology, Sorbonne Université, Paris, France, ³Biometrics, Janssen-Cilag B.V., Breda, Netherlands, ⁴University Hospitals Leuven, Leuven, Belgium, ⁵Division of Rheumatology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, ⁶Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Nasonova Research Institute of Rheumatology, Moscow, Russian Federation, ⁸Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁹Amsterdam Rheumatology and Immunology Center | Reade, Amsterdam, Netherlands, ¹⁰Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joined Academic Rheumatology Program, Athens University Medical School, Athens, Greece, ¹¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Cardiff, United Kingdom, ¹²Biometrics, Janssen-Cilag B.V., Moscow, Russian Federation, ¹³Biometrics, Janssen-Cilag B.V., Solna, Sweden, ¹⁴Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: The link between treatment recommendations for PsA (to aim for a state of remission or low disease activity (LDA))1,2 and patient-important outcomes has been…
Abstract Number: 637 • 2018 ACR/ARHP Annual Meeting
How to Define Remission and Low Disease Activity in Psoriatic Arthritis? an Analysis of 419 Patients with a Double Perspective, Based on Composite Scores and Patients’ and Physicians’ Perspectives
Clémence Gorlier¹, Deborah Puyraimond-Zemmour¹, Laura C. Coates², Ana-Maria Orbai³, Uta Kiltz⁴, Ying Ying Leung⁵, Penelope Palominos⁶, Juan D. Cañete⁷, Rossana Scrivo⁸, Andra Rodica Balanescu⁹, Emmanuelle Dernis¹⁰, Sandra Tälli¹¹, Adeline Ruyssen-Witrand¹², Martin Soubrier¹³, Sibel Zehra Aydın¹⁴, Lihi Eder¹⁵, Inna Gaydukova¹⁶, Ennio Lubrano¹⁷, Pascal Richette¹⁸, M. Elaine Husni¹⁹, Maarten de Wit²⁰, Josef S. Smolen²¹ and Laure Gossec²², ¹Sorbonne Université, PARIS, France, ²University of Oxford, Oxford, United Kingdom, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ⁶Rheumatology, Hospital de Clinicas de Porto Alegre, Santa Cecilia, Brazil, ⁷Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁸Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ⁹Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ¹⁰Service de Rhumatologie, CH du Mans, Le Mans, France, ¹¹East-Tallinn Central Hospital, Department of Rheumatology, Tallinn, Estonia, ¹²Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ¹³Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹⁴University of Ottawa, Ottawa, ON, Canada, ¹⁵Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ¹⁶North-western state medical university n.a. II Mechnikov, St. Petersburg, Russian Federation, ¹⁷Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy, ¹⁸Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, ¹⁹Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ²⁰Dept. Medical Humanities, Amsterdam Public Health (APH), VU University Medical Centre, Amsterdam, Netherlands, ²¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²²Sorbonne Universités, Paris, France
Background/Purpose: Remission (REM) or minimal/low disease activity (LDA) is the treatment goal in Psoriatic Arthritis (PsA). There is no consensus on definitions of REM/LDA. Recently,…
Abstract Number: 643 • 2018 ACR/ARHP Annual Meeting
Remission in Psoriatic Arthritis: Definition and Predictors
Samar AlHarbi¹, Justine Y. Ye², Ker-Ai Lee³, Vinod Chandran², Richard J. Cook³ and Dafna D Gladman¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: No validated definition of remission exists for psoriatic arthritis (PsA) to date. We previously identified 17.6% of our patients as having remission (no actively…
Abstract Number: 1607 • 2018 ACR/ARHP Annual Meeting
Achievement of Cdapsa Low Disease Activity or Remission Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psa in Subjects Treated with Apremilast
Laura C. Coates¹, Philip J. Mease², Frank Behrens³, Ana-Maria Orbai⁴, Alexis Ogdie⁵, Michele Brunori⁶, Lichen Teng⁶, Benoit Guerette⁶ and Josef S. Smolen⁷, ¹University of Oxford, Oxford, United Kingdom, ²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ³Division of Rheumatology, Goethe University and Fraunhofer IME-TMP, Frankfurt, Germany, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Celgene Corporation, Summit, NJ, ⁷Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Therapeutic targets for psoriatic arthritis (PsA) include the achievement of remission (REM) or low disease activity (LDA), measured by the Clinical Disease Activity Index…
Abstract Number: 1655 • 2018 ACR/ARHP Annual Meeting
Achieving Remission in Psoriatic Arthritis By Early Initiation of TNF Inhibition: A Double-Blind, Randomized, Placebo-Controlled Trial of Golimumab + Methotrexate Versus Placebo + Methotrexate
Leonieke van Mens¹, Jet de Jong², Inka Fluri¹, Marleen van de Sande³, Michael Nurmohamed⁴, M.R. Kok⁵, Arno van Kuijk⁶ and Dominique Baeten², ¹Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Clinical Immunology & Rheumatology, ARC | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴Rheumatology, Reade, Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, ⁵Rheumatology, Maasstad Ziekenhuis, Rotterdam, Netherlands, ⁶Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands
Background/Purpose: In inflammatory arthritis such as RA, early initiation of highly effective targeted treatments is a successful strategy to aim for sustained remission.1 Here we…
Abstract Number: 2570 • 2018 ACR/ARHP Annual Meeting
Probability of Achieving Low Disease Activity or Remission in Subjects with Active Psa Treated with Apremilast
Philip J. Mease¹, Frank Behrens², Dafna D Gladman³, Arthur Kavanaugh⁴, Michele Brunori⁵, Lichen Teng⁵, Benoit Guerette⁵, Rubén Queiro⁶ and Alexis Ogdie⁷, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Division of Rheumatology, Goethe University and Fraunhofer IME-TMP, Frankfurt, Germany, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of California, San Diego, School of Medicine, La Jolla, CA, ⁵Celgene Corporation, Summit, NJ, ⁶Rheum-Derm Unit, Hospital Universitario Central de Asturias, Oviedo, Spain, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: The ability to predict responses to apremilast (APR) could impact treatment decisions. This post-hoc analysis was conducted to (1) assess the predictive values of…
Abstract Number: 2572 • 2018 ACR/ARHP Annual Meeting
Predictors for Use of Secukinumab 300mg over 150mg in Psoriatic Arthritis: A Meta-Analysis of Four Phase 3 Trials By Machine Learning
Luminita Pricop¹, Corine Gaillez², Gregory Ligozio³, Xuan Zhu³ and David James³, ¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ²Novartis Pharma AG, Basel, Switzerland, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Subcutaneous secukinumab 150mg and 300mg are approved doses for the treatment of psoriatic arthritis (PsA) with the higher dose recommended for patients with anti-TNF inadequate…
Abstract Number: 2547 • 2017 ACR/ARHP Annual Meeting
the Ideal Target for Psoriatic Arthritis? Comparison of Remission and Low Disease Activity States in a Real Life Cohort
Leonieke van Mens¹, Arno van Kuijk², Dominique Baeten¹ and Laura C Coates³, ¹AMC, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ²Reade, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ³LIRMM, University of Leeds, Leeds, United Kingdom
Background/Purpose: Recommendations on psoriatic arthritis (PsA) state that the target of treatment should be remission or inactive disease with an alternative target of minimal or…
Abstract Number: 2550 • 2017 ACR/ARHP Annual Meeting
A New and Simpler Tool for Global Psoriatic Arthritis Assessment: Simplified Composite Psoriatic Disease Activity Index (sCPDAI)
Maria Laura Acosta Felquer¹, Musaab Elmamoun², Agnes Szentpetery^3,4, Phil Gallagher⁵, Oliver FitzGerald⁶ and Enrique R. Soriano⁷, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ³Rheumatology, Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁴Bone & Joint Unit, Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁵St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ⁶St. Vincent's University Hospital, Department of Rheumatology. UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland, ⁷Rheumatology Unit, Internal Mecine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: The heterogeneity of psoriatic arthritis ( PsA) that includes a possible combination of axial disease, peripheral arthritis, enthesitis, dactylitis, skin and nail involvement, makes…
Abstract Number: 1699 • 2016 ACR/ARHP Annual Meeting
RAPID3 Near Remission Shows Good Agreement with Minimal Disease Activity Criteria in Psoriatic Arthritis
Laura C. Coates^1,2, William Tillett^3,4, Theodore Pincus⁵, Arthur Kavanaugh⁶ and Philip S. Helliwell⁷, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ³Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ⁴Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵Rheumatology, Rush University Medical Center, Chicago, IL, ⁶Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ⁷NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: RAPID3 (routine assessment of patient index data) is a patient self-report index which is feasible in busy clinical settings to assess severity and change…
Abstract Number: 2766 • 2016 ACR/ARHP Annual Meeting
The Predictive Value of Patient’s and Evaluator’s Global Assessment and Tender and Swollen Joint Count Differences on Treatment Efficacy in Psoriatic Arthritis: Data from a Longitudinal Multicenter Study
Brigitte Michelsen^1,2, Eirik K Kristianslund¹, Hilde B Hammer³, Karen M Fagerli¹, Elisabeth Lie¹, Glenn Haugeberg^4,5 and Tore K Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ³Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Martina Hansens Hospital, Bærum, Norway, ⁵Dept. of Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: Discordance between patient’s and physician’s evaluation of disease activity may be challenging in psoriatic arthritis (PsA). The potential impact of such a difference on…
Abstract Number: 2935 • 2014 ACR/ARHP Annual Meeting
Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis
Barry J. Sheane¹, Arane Thavaneswaran², Dafna D. Gladman² and Vinod Chandran², ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose Methotrexate (MTX) is used as first-line treatment in psoriatic arthritis (PsA); however, the extent of the disease-modifying effect of MTX on PsA, if any,…
Abstract Number: 2485 • 2013 ACR/ARHP Annual Meeting
High Incidence Of Disease Recurrence After Discontinuation Of Disease Modifying Anti-Rheumatic Drug Treatment In Patients With Psoriatic Arthritis In Remission
Elizabeth Araujo¹, Stephanie Finzel¹, Dominik A. Schreiber², Matthias Englbrecht¹, Axel J. Hueber³, Francesca Faustini³, Juergen Rech³ and Georg Schett¹, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: In the era of modern anti-rheumatic therapy, it is now possible to contemplate the idea of clinical remission in patients with psoriatic arthritis (PsA).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].